Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 Net Current Asset Value is $0.40 as of Sep. 2025, which is 88% below its 10-year median of 3.23. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 75 Medical Distribution companies, Cellyan Biotechnology Co ranks better than 86.67% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Cellyan Biotechnology Co's net current asset value per share for the quarter that ended in Sep. 2025 was $0.40.
The historical rank and industry rank for Cellyan Biotechnology Co's Net Current Asset Value or its related term are showing as below:
HKPD'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.11 Med: 3.23 Max: 3.68
Current: 1.11
During the past 3 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cellyan Biotechnology Co was 3.68. The lowest was 1.11. And the median was 3.23.
HKPD's Price-to-Net-Current-Asset-Value is ranked better than 86.67% of 75
companies
in the Medical Distribution industry
Industry Median: 3.29
vs HKPD: 1.11
Cellyan Biotechnology Co (NAS:HKPD) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Cellyan Biotechnology Co Net Current Asset Value Related Terms
Cellyan Biotechnology Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Cellyan Biotechnology Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Net Current Asset Value Chart
HKPD vs COSM, SNYR, YI: Net Current Asset Value Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.40 mean?
Cellyan Biotechnology Co (HKPD) has a Net Current Asset Value of $0.40 as of Sep. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cellyan Biotechnology Co and its competitors. This is 88% below median its historical median of 3.23. Over the past decade, Cellyan Biotechnology Co's Net Current Asset Value has ranged from 1.11 to 3.68. According to the industry distribution chart, Cellyan Biotechnology Co ranks #10 out of 75 companies in the Medical Distribution industry, placing it in the top 13.3%.
Is Cellyan Biotechnology Co's Net Current Asset Value too high?
Cellyan Biotechnology Co's current Net Current Asset Value of $0.40 is 88% below median its 10-year median of 3.23. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 3.68. The Medical Distribution industry median Net Current Asset Value is 3.29. Cellyan Biotechnology Co's value of $0.40 is 87.8% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #10 out of 75 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Net Current Asset Value compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #10 out of 75 companies for Net Current Asset Value. This places Cellyan Biotechnology Co in the top 13% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 3.29. Cellyan Biotechnology Co's value of $0.40 is 87.8% below this benchmark. Historically, Cellyan Biotechnology Co's own Net Current Asset Value has ranged from 1.11 to 3.68 over the past decade. While the company's 10-year median is 3.23 vs. the industry median of 3.29, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.29, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Net Current Asset Value of $0.40 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Net Current Asset Value is $0.40, which is 88% below median its own 10-year median of 3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Net Current Asset Value of $0.40. The current Net Current Asset Value is $0.40, which is 88% below median its 10-year median of 3.23 and 87.8% below the Medical Distribution industry median of 3.29. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Net Current Asset Value is $0.40 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
